The MKRN2 Knockout Raji Polyclonal Cells consist of a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte cell line. This heterogeneous pool of cells carries targeted disruptions in the MKRN2 gene, providing a versatile loss-of-function model without clonal selection. The polyclonal format retains genetic diversity, closely mimicking population-level responses and enabling robust functional studies of MKRN2 in a lymphoma context.
The Raji cell line is a widely used human B lymphocyte model originally established from a patient with Burkitt lymphoma. These cells are Epstein-Barr virus (EBV)-positive and exhibit hallmark features of transformed B cells, including rapid proliferation and expression of B cell surface antigens. Raji cells serve as a critical platform for investigating B cell biology, lymphomagenesis, and immune signaling, making them an ideal host for dissecting MKRN2 function in B cell malignancies.
MKRN2 encodes an E3 ubiquitin-protein ligase that mediates the ubiquitination and subsequent proteasomal degradation of key substrates, most notably the oncogenic transcription factor c-Myc. This activity positions MKRN2 at the nexus of regulatory circuits governing cell proliferation and apoptosis in B lymphocytes. Upstream signals involving p53 and NF-??B converge on MKRN2, linking cellular stress and immune pathways to protein turnover. Through its interaction with ubiquitin-conjugating enzymes and the 26S proteasome complex, MKRN2 controls the stability of c-Myc and potentially other targets such as p53, thereby fine-tuning transcriptional programs critical for cell cycle progression and survival.
In the Raji lymphoma background, MKRN2 disruption offers a powerful tool to explore how ubiquitin-mediated proteolysis influences B cell malignancy. Given the central role of c-Myc deregulation in Burkitt lymphoma, ablating MKRN2 can reveal the impact of altered protein degradation kinetics on oncogenic signaling and tumor cell fitness. Additionally, Raji cells retain functional B cell receptor signaling components, permitting investigation of the interplay between ubiquitination, NF-??B activation, and antigen-driven responses. This model is particularly relevant for probing mechanisms of drug sensitivity or resistance in lymphomas dependent on c-Myc overexpression.
Researchers can apply these polyclonal knockout cells in a wide range of experimental contexts. Western blotting and RT-qPCR enable confirmation of MKRN2 loss and assessment of c-Myc protein levels, while proliferation and apoptosis assays quantify functional outcomes. Ubiquitination and co-immunoprecipitation assays facilitate detailed analysis of MKRN2-substrate interactions and proteasomal targeting. Flow cytometry can profile B cell markers to evaluate immune phenotype changes. The polyclonal population is suitable for drug screening campaigns aimed at identifying modulators of c-Myc-driven lymphoma growth. For further details or customized support, contact Ascent Research.
